Ujvira Trastuzumab 100 Mg Injection

Product Description

Ujvira 100mg Injection is a targeted therapy containing the active constituent trastuzumab emtansine. The U.S. Food and Drug Administration (FDA) approved trastuzumab emtansine on February 22, 2013, for treating patients with HER2-positive metastatic breast cancer who have previously received trastuzumab and chemotherapy. This medication is not recommended for adolescents and children under 18. Before taking this medicine, it is vital to inform your doctor if you have any blood clot disorders, liver disorders, or allergies.

Mechanism & Benefits

Ujvira Trastuzumab 100 Mg Injection functions as a monoclonal antibody specifically targeting the HER2 receptor present in certain types of breast and gastric cancers. By blocking these receptors, it hinders cancer cell proliferation and enhances the effectiveness of other cancer treatments, improving patient outcomes.


Proper Administration Process

This medication must be reconstituted using sterile water for injection before intravenous administration. Ujvira should be given only under the supervision of an oncologist in a clinical setting, and the dose is carefully calculated according to the patient's body weight for optimal safety and efficacy.


Patient Suitability and Storage

Ujvira is intended for adult patients diagnosed with HER2-positive breast or metastatic gastric cancer. The lyophilized powder must be stored in a refrigerator at 2C to 8C, and care should be taken to never freeze the product. Only use the injection as directed by a qualified healthcare professional.